Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Loving your body in a world where weight stigma helps sell GLP-1 drugs
Whether you’re living in a body that’s large or small, the rise of GLP-1 advertising and its use…
Northern Ireland moves to tackle obesity with new restrictions on unhealthy food promotions | Food Standards Agency
Obesity is one of the biggest public health challenges facing Northern Ireland, with 65% of adults living with…
Doctors And GLP-1 Users Respond To Trump’s ‘Fat Drugs’ Comments
The use of GLP-1s is skyrocketing throughout the world; 11% of American adults report taking the medications, up…
TGA issues warning over GLP-1-based drugs’ potential to cause rare eye disorder
The medicines regulator has issued a new safety warning for GLP-1-based drugs, like Ozempic, which could potentially cause…
Taste preference genes drive overeating and metabolic disease risk
Ever wonder why some people crave sweets while others can take them or leave them? Preliminary findings from…
From 98 Kg To 78 Kg: Woman Shares The Diet Plan That Helped Her Lose 20 Kg
There is a fine line between body shaming and expressing concern about someone’s obesity. Adity Bhargav’s story highlights…
Time-restricted eating may help lower dementia risk in older women
Results from a small clinical trial suggest it may be possible to reduce your risk of dementia by…
An enzyme might help fight against your body’s aging
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…
New GLP-1 Clinical Study Finds Calocurb Reduces Body Weight and Fat » World Business Outlook
Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, recently announced the publication…
Lilly to file for next-gen obesity drug approval in early 2027
Investing.com — Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in…
Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits
A large US health-record study suggests newer GLP-1 drugs may reduce alcohol-related acute-care visits, but the findings remain…